Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background.

American journal of human genetics - 5 Oct 2023

Zhang Cong, Shestopaloff Konstantin, Hollis Benjamin, Kwok Chun Hei, Hon Claudia, Hartmann Nicole, Tian Chengeng, Wozniak Magdalena, Santos Luis, West Dominique, Gardiner Stephen, Mallon Ann-Marie, Readie Aimee, Martin Ruvie, Nichols Thomas, Beste Michael T, Zierer Jonas, Ferrero Enrico, Vandemeulebroecke Marc, Jostins-Dean Luke

Abstract excerpt

Response to the anti-IL17 monoclonal antibody secukinumab is heterogeneous, and not all participants respond to treatment. Understanding whether this heterogeneity is driven by genetic variation is a key aim of pharmacogenetics and could influence precision medicine approaches in inflammatory diseases. Using changes in disease activity scores across 5,218 genotyped individuals from 19 clinical trials across four...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arthritis, Psoriatic
Share to Arthritis, Rheumatoid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asthma and respiratory diseases

Share to Autoimmune and Inflammatory Disorders Research

Share to Genotype

Share to Psoriasis

Share to Psoriasis: Treatment and Pathogenesis

Source

Open in PubMed Open full text

Identifiers

PMID: 37659414
DOI: 10.1016/j.ajhg.2023.08.010
PMCID: PMC10577077

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background.PMID 37659414Read ↗

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.Semantic proximity Read ↗

Pharmacogenetics Update on Biologic Therapy in PsoriasisSemantic proximity Read ↗

Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?Semantic proximity Read ↗

Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies.Semantic proximity Read ↗

HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis.Semantic proximity Read ↗

ERAP1 and ERAP2 gene variants as potential clinical biomarkers of anti-interleukin-17A response in psoriasis vulgaris.Semantic proximity Read ↗

Genetically Proxied Interleukin-13 Inhibition Is Associated With Risk of Psoriatic Disease: A Mendelian Randomization Study.Semantic proximity Read ↗

Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.Semantic proximity Read ↗

Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.Semantic proximity Read ↗

Pharmacogenetic Analysis of Variants in IL-6 Signaling and Response to Modern Therapeutic Approaches in Greek Patients with Atopic Dermatitis.Semantic proximity Read ↗

Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice.Semantic proximity Read ↗

Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.